David Heyens has been appointed to the new role of president of Catalent Asia Pacific, reporting to Catalent’s president and chief executive officer, John Chiminski. Mr. Heyens will work to drive growth in the region following the company’s recent expansion into China and will build on its regional operations in Japan, Australia and Singapore.
“This appointment comes at an important moment in our business, as we launch our two new joint ventures in China, for softgel technologies and clinical supplies, and focus more growth resources in Asia Pacific,” said Mr. Chiminski. “Bringing Dave’s proven leadership to this region is hugely beneficial for both our customers and our business.”
Aris Gennadios, Ph.D. will replace Mr. Heyens as president of Catalent Softgel Technologies. He will also report to Mr. Chiminski and will have full strategic responsibility for global softgel development, delivery and supply business with 10 global manufacturing facilities.
“Aris is an outstanding leader and a widely respected industry veteran, known for his expertise and passion for delivering better treatments for patients across an ever expanding set of challenging molecules in softgel drug delivery technology” said Mr. Chiminski. “We are very excited to have him join our executive team and extend the momentum and growth that we are driving in our flagship business.”
Mr. Heyens served as president of the Softgel Technologies business since June 2007. He joined the company in 1995 and served in a variety of capacities, including president of packaging services, senior vice president of global sales and marketing, president of North America Softgel Technologies, and general manager for the Canadian softgel business. Prior to joining Catalent, he held leadership roles in sales and marketing at Baxter and Procter & Gamble.
Dr. Gennadios has held roles of increasing responsibility since joining the company in 2002 in both advanced technologies and development solutions. He served as general manager of the company’s Somerset, NJ site, and in 2010 became vice president and general manager of Catalent’s Rx Softgel Technologies business. Later he served as vice president and general manager of the overall global Softgel Technologies business.